Virpax Pharmaceuticals Engages Torreya Capital to Advise on Global Partnering Efforts

Virpax Pharmaceuticals

BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX), announced recently that the Company has engaged Torreya Capital, LLC (Torreya) to serve as the exclusive financial advisor for the Company’s partnering and licensing efforts in strategic global markets.

Torreya is a global investment bank that has facilitated more than $100 billion worth of transactions in the life sciences industry since its inception in 2007.

“We are excited to be working with Torreya to expand our partnerships in key markets,” stated Anthony Mack, Chairman and CEO of Virpax Pharmaceuticals. “There is a growing global demand for non-opoid, non-addictive pain treatments and we believe that our product candidates, Epoladerm™, Probudur™, and Envelta™ can offer a competitive advantage in their addressable markets,” concluded Mr. Mack.

“We look forward to helping Virpax Pharmaceuticals find strong regional partners for their innovative acute and chronic pain product candidate pipeline,” said Tom Bird, Partner of Torreya. “Virpax’s product candidates incorporate its proprietary technologies that may enable the product candidates to deliver enhanced benefits with non-addictive pain relief.”

READ:  Trevena Announces First Patient Enrolled in NIH-Funded ACTIV-4 Host Tissue Trial of TRV027 for COVID-19

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.